Asthma remains a significant health concern in Australia, affecting approximately 2.8 million people, or about 11% of the population. Notably, in 2022–2023, there were over 31,000 hospitalisations where asthma was the main diagnosis, with nearly half (43%) of these cases involving children aged 14 or under. These figures underscore the critical need for effective and efficient asthma management tools in both clinical and community settings. Source: Asthma Australia
This clinical performance review highlights the results of independent testing conducted by the University of Western Australia on the Livingstone Foldable Cardboard Spacer. Designed for single-use convenience and reliable drug delivery, the spacer demonstrated a 25% increase in salbutamol output per actuation compared to a market-leading alternative. With strong results across key respiratory metrics and a compact, hygienic design, the Livingstone spacer offers a practical solution for high-demand environments such as hospitals, aged care, ambulance services, and schools.
